VetDC, Inc. Acquires Novel, Targeted Anti-Cancer Drug from Pathway Therapeutics, Inc. VetDC, Inc., today announced that the company has acquired from Pathway Therapeutics, Inc. all rights to Pathway’s investigational class of anti-cancer molecules, including PWT33597 (renamed as VDC-597) and its … Keep Reading